CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaomin, Zhu, Lingling, Zhang, Hui, Chen, Shanshan, Xiao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226391/
https://www.ncbi.nlm.nih.gov/pubmed/35757715
http://dx.doi.org/10.3389/fimmu.2022.927153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226391/
https://www.ncbi.nlm.nih.gov/pubmed/35757715
http://dx.doi.org/10.3389/fimmu.2022.927153

Ejemplares similares